IP Library Granted Patent US 7,727,223
Granted Patent B2
US 7,727,223 · App. 10/489,265 · Granted Jun 1, 2010

Drug delivery technology

Assignee: Glide Pharmaceutical Technologies Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,727,223
App. No.
10/489,265
Granted
Jun 1, 2010
Kind
B2
Abstract

The invention relates to a novel drug delivery technology. More particularly the invention relates to a method of delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient: to a throwaway or reusable device for delivering at least one therapeutic compound or a formulation comprising the at least one therapeutic compound to a patient in a manner as set out by the method; to a pioneer projectile form use in said method; to formulations for use in said method and to an injectate comprising a pioneer projectile and formulation. It also relates to a disposable component containing either a pioneer projectile or an injectate.

Claims (9)

1. A method of delivering at least one therapeutic compound to a human or animal in the form of a needleless injection comprising:

providing an injection device comprising a casing having an aperture and a spring for storing energy, an ejector pin for pushing an injectate through the aperture wherein the injectate comprises at least one therapeutic compound;

placing the aperture of the device close to or in contact with the skin of a human or animal;

actuating the device by causing the spring to release its stored energy generating a force that causes the injector pin to engage the injectate and push it out of the aperture as a single unit;

penetrating the skin of the human or animal with the injectate at a velocity of less than 100 m/s wherein the injectate has a maximum diameter of less than 3 mm and is left in the human or animal and wherein the ejector pin continues to push the injectate beyond the device and into the human or animal.

2. The method of claim 1 wherein the at least one therapeutic compound is selected from the group of prophylactic, diagnostic and therapeutic substances.

3. The method of claim 1 wherein the injectate further comprises a pioneer projectile.

4. The method of claim 1 wherein the spring is a mechanical spring.

5. The method of claim 1 wherein the therapeutic compound is intermixed with an excipient or excipients.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2019
From: GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
To: ENESI PHARMA LIMITED
Reel/Frame 049811/0014 →
CHANGE OF NAME Recorded Nov 8, 2007
From: CARETEK MEDICAL LIMITED
To: GLIDE PHARMACEUTICAL TECHNOLOGIES LIMITED
Reel/Frame 020087/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2004
From: POTTER, CHARLES DAVID OGILVY; POTTER, DAVID S.
To: CARETEK MEDICAL LIMITED
Reel/Frame 015760/0935 →
Priority Claims (1)
GB 0121914.6 · Sep 11, 2001 · national
Continuity (1)
Related Publication 20050013840A1 · Jan 20, 2005